Focus: Cognito Therapeutics develops device-based brain stimulation therapies focused on neurodegenerative diseases, specifically Alzheimer's disease. The company is a publicly traded biotech with a specialized focus on non-pharmacological neuromodulation approaches.
Profile data last refreshed 1h ago · AI intelligence enriched 2mo ago
Stable — net +3 jobs in 30d
4 added, 1 removed. Backfill posture.
Cognito represents a high-risk, high-reward early-stage device play suitable for risk-tolerant professionals betting on novel modalities, but limited hiring suggests the company may face resource constraints.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Cognito Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Cognito Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Cognito Therapeutics - 2026 Funding Rounds & List of Investors - Tracxn
Cognito Therapeutics - 2026 Funding Rounds & List of Investors Tracxn
Cognito Therapeutics, Ochsner team up for new brain health approaches - Pharmaceutical Technology
Cognito Therapeutics, Ochsner team up for new brain health approaches Pharmaceutical Technology
Cognito Therapeutics Appoints Thomas Fagan as Executive Vice President, Alzheimer’s Portfolio - Business Wire
Cognito Therapeutics Appoints Thomas Fagan as Executive Vice President, Alzheimer’s Portfolio Business Wire
$105 Million Brings Cognito, And Neurotech, to a Pivotal Stage - Forbes
$105 Million Brings Cognito, And Neurotech, to a Pivotal Stage Forbes
Cognito raises $105M to bring Alzheimer’s treatment device to market - MedTech Dive
Cognito raises $105M to bring Alzheimer’s treatment device to market MedTech Dive
Cognito Therapeutics closes oversubscribed $105M Series C - MassDevice
Cognito Therapeutics closes oversubscribed $105M Series C MassDevice
Showing 6 of 10 news items
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles